© 2014 American Association for Clinical Chemistry
The American College of Medical Genetics and Genomics (ACMG) 9 recommends that every clinical exome test be accompanied with a report on pathogenic findings in 56 genes with well-known clinical importance (1 ) . This controversial guidance (2-7 ) assumes that the analytical performance of clinical exome sequencing returns DNA sequence data of sufficient quality to assess genetic findings that were not validated during the initial development of the clinical exome test. In prior studies, the coding sequence not covered by exome sequencing has ranged from 1.4% to 39.1% (8 -11 ) . The extent of coverage depends on the source of DNA used for sequencing (saliva, white blood cells), biochemical characteristics of the targeted region (e.g., GC content), methodology of sequence enrichment (e.g., liquid phase baits), sequencing technology (e.g., sequence by synthesis), and basic quality parameters (e.g., minimum depth of coverage). Moreover, no general consensus has been reached regarding the establishment and reporting of false-negative rates in clinical exome sequencing. Because the ACMG guideline recommends reporting on pathogenic findings in 56 genes with actionable clinical significance, patients and physicians may expect that these genes have adequate depth and breadth of sequencing coverage in a clinical exome analysis. This study surveyed the potential low sequencing coverage at potentially significant nucleotide positions that may contribute to falsenegative reporting of pathogenic variants in the 56 ACMG genes.
Materials and Methods

INSTITUTIONAL REVIEW
We obtained human exome sequencing data from several sources. Data from Thomas Jefferson University and the University of Texas Southwestern Medical Center were obtained under separate research protocols approved by their respective Institutional Review Boards.
EXOME CAPTURE METHODS
The TargetSeq (TargetSeq™ Target Enrichment Kit, Life Technologies), SureSelect v4 (SureSelect™ Human All Exon Target Enrichment System v4ϩUTR, Agilent Technologies), and TruSeq (TruSeq™ Exome Enrichment Kit, Illumina) exome capture methods were optimized before the analysis of the samples in this study ( Table 1 ). All of the exome capture methods in this study were solution-phase capture. For TargetSeq and SureSelect v4, 3 g genomic DNA was used. For TruSeq, 1 g genomic DNA was used.
GENOMIC DNA AND KIT PREPARATION
We used genomic DNA in each of the exome evaluations ( Table 1 ). The sample type and method of purification differed for each type of exome evaluation. Samples for TargetSeq and SureSelect v4 capture were prepared from genomic DNA extracted from whole blood extraction kits (QIAamp DNA Midi, Qiagen). TruSeq exome capture was prepared from genomic DNA either extracted from whole blood extraction kits (Gentra Systems Autopure LS, Qiagen) or submitted as purified genomic DNA to a core facility.
SEQUENCING
TargetSeq and SureSelect v4 libraries were sequenced on a SOLiD 5500xl (Life Technologies). We validated the SureSelect v4 exome sequencing on the SOLiD 5500xl for clinical use under the US Clinical Laboratory Improvement Amendments; in addition, the laboratory is inspected and accredited by the College of American Pathologists. We performed sequencing of the Illumina TruSeq exome libraries on a HiSeq 2000 (Illumina) in a research core facility.
ALIGNMENT AND GENOTYPING
All sequence reads were mapped to the hg19 reference genome (12 ) . We analyzed SOLiD 5500xl sequence reads with an iterative mapping approach using Applied Biosystems LifeScope Genomic Analysis Software v2.5. Each sequence read was allowed to have a maximum of 2 mismatches. Illumina HiSeq 2000 sequence reads were mapped with the Short Read Mapping Package (13 ) . The sequence reads were qualitytrimmed with the reads' associated quality values by use of Cutadapt (14 ) . During mapping, mismatches (replacements) were allowed that did not comprise Ͼ4% of a given read's length; no insertions or deletions were permitted. For all sequence mappings, only those reads mapping uniquely to the human genome were maintained.
CALCULATION OF COVERAGE OF TARGET REGIONS
We calculated coverage across the exome by intersecting sequence reads with the respective exome capture kit bed files (targeted regions) using the Bedcov flag in SamTools (15 ) and the coveragebed module of BED tools (16 ) . Each application identifies the number of base pairs and number of sequence reads mapping to each region of the bed file. We examined targeted exons for adequacy of breadth of coverage by setting a minimum depth of coverage at Ն20ϫ. An exon was considered to have a low breadth of coverage for a specific exome method if any base position within the exon of interest had Ͻ20ϫ depth of coverage in more than half of the samples examined.
We also determined depth of coverage for nucleotide positions in the 56 ACMG genes that may be reported as sites of clinically significant variants. Singlenucleotide variants (SNVs) that have been reported to occur within the 56 ACMG genes were extracted from HGMD ® (Human Gene Mutation Database) Professional 2013.4 (BIOBASE Biological Databases). The SNVs categorized by HGMD as "DM" [disease causing (pathological) mutation] were further analyzed. These DM variants were then used to create a BED file for the determination of the depth of coverage.
Results
The exome sequencing datasets examined in the present study demonstrated the heterogeneity of performance among various methods (Table 1) . TargetSeq and SureSelect v4 had the highest number of mapped reads, with means of 206 million and 199 million, respectively. In terms of base pairs generated in the designed target regions, SureSelect v4 and TruSeq were the highest, at 7.6 gigabases and 9.1 gigabases, respectively. All of the datasets examined had a mean depth of coverage across all target regions ranging from 74ϫ to 120ϫ. The depth of coverage was inversely correlated with the coverage of target regions. At the low end of stringency (Ͼ5ϫ), the lowest coverage of target regions was 91%; however, with higher stringency (Ͼ20ϫ), the best method covered only 87% of target regions (SureSelect v4). The SureSelect v4 (clinical method) had 92% of targeted nucleotides covered at Ͼ10ϫ. In comparison, a recent survey of clinical exome laboratories demonstrates a typical metric of Ͼ10ϫ depth of coverage for 90%-95% of target nucleotides (17 ) .
The 56 genes cited in the ACMG guideline have a total of 18 336 SNVs annotated in HGMD as pathogenic (DM). None of these HGMD DM variants were identified in any of the samples examined. The nucleotide positions of the 18 336 HGMD pathogenic sequence variants were examined for depth of coverage. Although a recent next-generation sequencing laboratory standard described the use of depth of coverage between 10ϫ and 20ϫ at a given nucleotide position (18 ) , the present study used a minimum depth of coverage of Ͼ20ϫ at a nucleotide position on the basis of studies examining the depth of coverage necessary for accurate base calling (8, 10, 11, 19 -21 ) .
When the 3 exome methods were compared by HGMD variant locations, substantial differences were seen in both design and sequencing coverage (Fig. 1 ). The Venn diagram shows the variant locations that were not in the capture probe designs for the 3 methods examined. A high number of variant locations were not directly covered in the capture probe designs of SureSelect, TargetSeq, and TruSeq (2352, 1779, and 719, respectively) ( Fig. 1A) . In addition to the variants not covered in the method design, the number of variant locations with low depth of sequencing coverage (Ͻ20ϫ) also examined for SureSelect, TargetSeq, and TruSeq are 842, 1295, and 1269, respectively (Fig. 1B) . In the sequencing results of the 3 methods, low coverage was seen for multiple variant locations, but the sequencing coverage was better than the designed capture probe coverage for SureSelect and TargetSeq. Although the variant locations may be absent in the designed capture probes, the variant location may be sequenced if a nearby region has a successful capture.
An aggregate analysis of the clinical exome test for HGMD variant coverage in each of the 56 ACMG genes was performed (Fig. 2) We analyzed exons with inadequate coverage in more than half the samples examined for each method (Table 3) 
Discussion
When the 18 336 pathogenic variant positions from 56 genes were examined in aggregate, the clinical exome data had approximately 90% of variant locations at Ն20ϫ depth of coverage (Fig. 2) . However, when examined at the level of individual genes, the paucity of coverage prevented analysis of many variant positions. The nucleotide positions of 18336 HGMD pathogenic variants in the 56 ACMG genes were examined for absence from the design of 3 exome capture kits (A). In addition, exome sequencing from the 3 kits was examined for low depth of coverage (Ͻ20ϫ) of the 18336 HGMD pathogenic variants in at least half of the samples examined for each kit (B). SureSelect (n ϭ 12), TargetSeq (n ϭ 33), TruSeq (n ϭ 12). For each graph, the median is the bolded hash mark within the rectangle. The left end of the rectangle is the 25th percentile, and the right end of the rectangle is the 75th percentile. The whiskers extend to Ϯ1SD from the mean. WT1, Wilms tumor 1; VHL, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase; TSC2, tuberous sclerosis 2; TPM1, tropomyosin 1 (␣); TP53, tumor protein p53; TNNT2, troponin T type 2 (cardiac); TNNI3, troponin I type 3 (cardiac); TMEM43, transmembrane protein 43; STK11, serine/threonine kinase 11; SMAD3, SMAD family member 3; SDHB, succinate dehydrogenase complex, subunit B, iron sulfur (Ip); RYR2, ryanodine receptor 2 (cardiac); RET, ret proto-oncogene; RB1, retinoblastoma 1; PTEN, phosphatase and tensin homolog; PRKAG2, protein kinase, AMP-activated, gamma 2 non-catalytic subunit; PKP2, plakophilin 2; NF2, neurofibromin 2 (merlin); MYLK, myosin light chain kinase; MYL2, myosin, light chain 2, regulatory, cardiac, slow; MYL3, myosin, light chain 3, alkali; ventricular, skeletal, slow; MYH7, myosin, heavy chain 7, cardiac muscle, beta; MYH11, myosin, heavy chain 11, smooth muscle; MYBPC3, myosin binding protein C, cardiac; MUTYH, mutY homolog; MSH2/6, mutS homolog 2/6; MLH1, mutL homolog 1; MEN1, multiple endocrine neoplasia I; LMNA, lamin A/C; LDLR, low density lipoprotein receptor; FBN1, fibrillin 1; DSP, desmoplakin; DSG2, desmoglein 2; DSC2, desmocollin 2; CACNA1S, calcium channel, voltage-dependent, L type, ␣1S subunit; BRCA1/2, breast cancer 1/2, early onset; APC, adenomatous polyposis coli; ACTA2, actin, alpha 2, smooth muscle, aorta.
The clinical exome tests had 7 genes where Ͼ50% of the HGMD variant locations had inadequate coverage. This inadequacy of coverage in a subset of 56 genes from exome sequencing is due to a combination of factors, including design of capture probes, high-GCcontent targets that may be difficult to capture and/or sequence, and pseudogenes. These factors have been previously discussed in the context of the overall analytical performance of exome sequencing (9 ) .
The ACMG "incidental findings" guideline recommends that clinical laboratories issue a disclaimer that the additional 56 clinically important genes exam- ined may not have the same quality or comprehensiveness as tests specifically designed to test for these genes. However, from the perspective of patients and clinicians, the consent or notification of testing for the ACMG 56 genes may create the false expectation that a sufficient genetic evaluation of these genes will be performed, regardless of a laboratory disclaimer. Indeed, the authors of the guideline acknowledge that physicians and their patients could interpret an indeterminate result because of lack of coverage of a clinically important nucleotide position as a negative result. The 18 336 nucleotide positions used in this study are an overestimate of the true pathogenic variants in the 56 genes. Variants in the HGMD database have been shown to be occasionally incorrectly annotated as pathogenic secondary to errors in the experimental literature or database errors (22 ) . Indeed, it has been observed that approximately 80% of the HGMD variants classified as disease causing have an allele frequency of Ͼ5% in the 1000 Genome Database; by definition, a rare variant has Ͻ5% allele frequency in a population (23 ) . However, the evaluation of depth of coverage at these 18 336 variant positions provides a uniform tool for surveying the quality of exome datasets for reporting on individual genes. The focus of this study was on adequate depth of coverage to analyze variants in the context of clinical testing. However, additional quality metrics need to be examined in future studies, including the accuracy of alignment and base calling. A recent study has demonstrated significant discordance between software programs that perform alignment and base calling (24 ) . In the present study, 15 exome datasets were examined by 5 commonly used alignment and variant-calling software combinations. The SNV concordance between the 5 software combinations was only 57.4%. The indel (insertion or deletion of multiple bases) concordance was only 26.8%. Thus, not only is the exome capture method and sequencing impor- Some experts have advocated that whole-genome sequencing may have fewer quality issues than exome sequencing, albeit at a much higher resource requirement for sequencing, data storage, and computational power. However, a recent study of clinical wholegenome sequencing reveals that a subset analysis of the 56 ACMG genes has inadequate coverage for variant detection in 9%-17% of genes (25 ) . The concept of deviation from uniform sequencing coverage has been termed bias, and each capture method and sequencing technology has differences in coverage bias (26 ) . This bias is an explanation for exome samples having good mean or aggregate coverage statistics but poor coverage at specific genes or variant locations.
Protocol modifications that are well known for optimization of PCR reactions can be used to decrease coverage bias in exome sequencing and other enrichment-based next-generation sequencing technologies. Previous studies that focused on optimizing exome sequencing have explored techniques such as changing DNA polymerase, temperature ramp rate, and denaturation time or adding betaine or tetramethylammonium chloride (27, 28 ) . These modifications have been specifically used to address AT-or GC-rich target regions. In addition to modifying the reaction conditions or adding chemical additives, there are successful examples of adding high concentrations of capture probes (spike-in) to regions with decreased coverage (29, 30 ) . In 1 example, the baseline exome test covered only 75% of 3000 clinically relevant genes (with a requirement for Ն20ϫ depth of coverage at every coding nucleotide); however, with the addition of a spike-in reagent containing a high concentration of probes targeted to low-coverage regions, 97% of 3000 clinically relevant genes had adequate coverage (29 ) . These modifications may be used to decrease coverage bias and improve the overall quality of data from exome sequencing tests.
The quality of clinical exome sequencing data should be taken into consideration with the ongoing discussion on the return of "incidental findings." Examination of depth of coverage at specific clinically significant variant positions as performed by this study may be a useful routine quality metric for clinical exome/genome tests. If a clinical laboratory plans to report subsets of genes from exome data, the target regions of these genes should be analytically validated before clinical implementation. In the short term, laboratories should consider supplementing exome methods with assay modifications or Sanger sequencing to fill in regions with poor coverage. In the long term, the heterogeneous and occasional poor depth of coverage in this subset of 56 genes illustrates the opportunity for further innovation in next-generation sequencing methods. 
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